Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
183 Leser
Artikel bewerten:
(1)

ClariMed Inc. Acquires We Are Human, Expanding Growth into Southeast Market

We Are Human's Expert Team and Atlanta-Based Usability Lab Join ClariMed's Growing Network; Founder Annmarie Nicolson Appointed as Principal

CHADDS FORD, Pa., Aug. 12, 2025 /PRNewswire/ -- ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, today announced the strategic acquisition of We Are Human, a UK and US-based consultancy specializing in user-focused design and research in MedTech innovation. The acquisition expands ClariMed's geographic reach into the Southeast through We Are Human's state-of-the-art Atlanta research facility while advancing the company's mission to enable innovative, human-centered medical technologies and make them accessible to communities that need them.

We Are Human, a ClariMed Company

Annmarie Nicolson, founder of We Are Human, will join ClariMed as Principal, bringing her extensive experience in early-stage formative research, contextual inquiry, and UX research for MedTech innovation to the leadership team. The acquisition brings the complete We Are Human team and their Atlanta research facility into the ClariMed family, expanding the company's presence in the Southeast region.

"This acquisition represents our continued commitment to our user-centered foundation while expanding our reach and strengthening our capabilities," said Kelley Kendle, CEO of ClariMed. "Regional variability allows us to better address our patients' needs and advance our mission to make medical technology safer, more intuitive, and more impactful for the people who need it most. This isn't just a merger of capabilities - it's a deep alignment of values."

The acquisition strengthens ClariMed's position as an integrated medical device services partner, expanding specialized expertise in user experience research, regulatory compliance, and design validation across both US and UK markets. We Are Human brings ISO 13485 certification and extensive experience with IEC-62366 and FDA Guidance requirements, having conducted research with hundreds of healthcare professionals, lay persons and diverse patient groups. The Atlanta laboratory will serve as ClariMed's newest research facility, offering access to diverse study populations in the Southeast while supporting the company's growing client base.

"Joining ClariMed represents an exciting opportunity to amplify our impact in healthcare through human-centered research and design," said Annmarie. "Both organizations have a long-standing commitment to putting users first and creating products that truly make a difference in people's lives. This shared dedication to excellence and user-centered principles positions us to deliver even more meaningful solutions- both to our clients and, to the patients and healthcare providers who rely on innovative medical technology every day."

The integration of We Are Human establishes ClariMed's first Southeast location, joining strategic offices across the United States and internationally, including Chadds Ford, PA; Cambridge, MA; San Jose, CA; Cambridge, UK; Leeds, UK; and now Atlanta, GA. This expanded geographic network enhances ClariMed's ability to serve global clients while accessing diverse talent pools and participant populations for user research and usability testing.

This acquisition aligns with ClariMed's growth strategy of building comprehensive, human-centered solutions for medical device development. The combined expertise of both organizations positions ClariMed to better serve pharmaceutical and medical device manufacturers seeking to accelerate time to market while enhancing patient safety and user experience.

About ClariMed

ClariMed is a human-centered development and regulatory practice for medical products developed by pharmaceutical and medical device manufacturers. Our best-of-breed professional services cultivate innovation while ensuring the safe and effective use of medical products. With offices across the United States and United Kingdom, ClariMed delivers comprehensive solutions that integrate human factors at the core of device development and regulatory pathways. Visit us at www.clarimed.com.

About We Are Human

Founded in 2020, We Are Human is an ISO 13485 certified consultancy, based in the UK and US specializing in Human Factors, User Research and UX, with deep expertise in human-centered research and design for healthcare. The company was founded on the belief that human needs should be at the heart of design, striving to improve quality of life, health, and wellbeing through product development. We Are Human brings extensive experience in Human Factors and Usability Engineering standards and regulatory requirements for medical device development, including IEC-62366 and FDA Guidance, with a track record of collaborating with clients across Medical Devices, Combination Products, FemTech, Digital Health and over-the-counter (OTC) products.

For media inquiries, please contact: press@clarimed.com

ClariMed: Designing the Future of Health

Photo - https://mma.prnewswire.com/media/2748400/We_Are_Human.jpg
Logo - https://mma.prnewswire.com/media/1991389/ClariMed___Logo_v2.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/clarimed-inc-acquires-we-are-human-expanding-growth-into-southeast-market-302527106.html

© 2025 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.